Morgan Stanley Maintains Equal-Weight on Chemours, Raises Price Target to $21

Benzinga Newsdesk www.benzinga.com Positive 66.8%

Neg 0% Neu 0% Pos 66.8%

Morgan Stanley analyst Vincent Andrews maintains Chemours (NYSE:CC) with a Equal-Weight and raises the price target from $17 to $21.